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Zusammenfassung
Hintergrund: Die Epstein-Barr-Virus(EBV)-assoziierte
Posttransplantations-lymphoproliferative Disease (PTLD)
ist eine gefürchtete Komplikation nach allogener häma-
topoetischer Stammzelltransplantation (HSCT). Insbe-
sondere bei Befall des zentralen Nervensystems (ZNS)
ist die Behandlung auf Grund der unsicheren Liquorwirk-
samkeit der meisten Chemotherapeutika als auch von
EBV-spezifischen zytotoxischen T-Spenderzellen schwie-
rig. Der monoklonale Anti-CD20-Antikörper Rituximab
wurde in den letzten Jahren bei Patienten mit EBV-PTLD
intensiv untersucht. Allerdings wurde bislang lediglich
von 8 Patienten mit ZNS-Befall eines B-Zell-Lymphoms
berichtet, bei denen eine Therapie mit Rituximab erfolg-
te. Kasuistik: Eine 24-jährige Patientin hatte wegen einer
akuten T-lymphoblastischen Leukämie in zweiter kom-
pletter Remission eine allogen-unverwandte, T-Zell-
depletierte HSCT erhalten. 10 Monate später wurde eine
EBV-assoziierte PTLD diagnostiziert. Neben peripheren
Lymphomen und B-Symptomen zeigte die Patientin neu-
rologische Symptome. Die Liquoruntersuchung erbrach-
te den Befund einer Meningeosis lymphoblastica im Rah-
men des EBV-Lymphoms. Die Behandlung mit Rituximab
und dem Virustatikum Cidofovir führte zu einer komplet-
ten Remission mit Rückbildung der peripheren Lympho-
me und Verschwinden der neurologischen Symptomatik.
Außerdem wurde die PCR-Kontrolle auf EBV-DNA so-
wohl im Plasma als auch im Liquor negativ. Schluss-
folgerung: Die Kombination von Rituximab und Cidofovir
erscheint als eine interessante Therapiealternative für
Patienten mit EBV-assoziierter PTLD und ZNS-Befall.
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Summary
Background: Epstein-Barr virus(EBV)-associated post-
transplant lymphoproliferative disease (PTLD) is a seri-
ous complication after allogeneic hematopoietic stem
cell transplantation (HSCT). Especially in cases with in-
volvement of the central nervous system (CNS) treat-
ment is difficult because the efficacy of most chemother-
apeutic agents as well as EBV-specific cytotoxic donor T
cells in liquor is uncertain. In the last years the anti-CD20
monoclonal antibody Rituximab was intensively investi-
gated in the treatment of EBV-PTLD. However, only 8 pa-
tients with B-cell lymphoma and CNS involvement treat-
ed with Rituximab were reported. Case Report: A 24-
year-old female patient with acute T-lymphoblastic
leukemia in second complete remission had received al-
logeneic, unrelated, T-cell depleted HSCT. 10 months
later an EBV-associated PTLD was diagnosed. Beside
peripheral lymphomas and B symptoms the patient
showed neurological symptoms. Examination of the
cerebrospinal fluid (CSF) revealed a meningeosis lym-
phoblastica caused by the EBV lymphoma. Treatment
with Rituximab and the antiviral drug Cidofovir led to
complete remission with regression of the peripheral
lymphomas and disappearance of the neurological
symptoms. In addition, the PCR control on EBV DNA
became negative in the plasma as well as in CSF. Conclu-
sion: The combination of Rituximab and Cidofovir ap-
pears as an interesting alternative treatment in patients
with EBV-associated PTLD and CNS involvement. 
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Introduction 
Dependent on additional risk factors the incidence of Ep-
stein-Barr virus(EBV)-associated post-transplant lymphopro-
liferative disease (PTLD) varies from 1–25% [1–4]. A signifi-
cantly increased incidence of PTLD after allogeneic HSCT
was reported in patients with T cell depleted grafts, after in-
tensive treatment of graft-versus-host-disease (GvHD), and
in cases with advanced stages of acute GvHD (grades 3 or 4)
[3, 5]. The pathogenetical model for the development of
PTLD includes the increased proliferation of EBV-infected B
lymphocytes and its insufficient immune control by T cells. In
addition, genetic mutations in infected proliferating B lym-
phocytes lead to transformed malignant cells and the develop-
ment of aggressive malignant lymphoma [6]. 
Both clinical course as well as morphology of these disorders
are very heterogenous [3]. However, there is a high frequency
of extranodal involvement [6]. Treatment strategies include
withdrawal of immunosuppression [3], infusion of unselected
donor leukocytes or EBV-specific cytotoxic donor T cells [1,
7–9], application of antiviral drugs and combination
chemotherapy [10–13]. Moreover, the use of specific anti-B-
cell monoclonal antibodies (anti-CD20, -CD21, -CD24) was
intensively examined over the last years [4, 14–17]. We here
report the successful treatment of an EBV-associated PTLD
including CNS involvement with the combination of anti-
CD20 monoclonal antibody Rituximab and antiherpesvirus
agent Cidofovir.
Case Report
A 24-year-old female patient with acute T-lymphoblastic leukemia in sec-
ond complete remission received T-cell depleted, HLA-DRQB1-
micromismatched HSCT from an unrelated donor in February 1999.
Conditioning regimen consisted of 1200 cGy fractionated total body irra-
diation, cyclophosphamide (60 mg/kg × 2), etoposide (30 mg/kg × 1) and
antithymocyte globulin (ATG) Merieux (2.5 mg/kg × 4). The graft con-
tained 8.8 × 106/kg CD34-positive cells. Following transplantation the pa-
tient received T-cell addback consisting of 1 × 105/kg and 1 × 106/kg CD3-
positive cells, respectively, on days +14 and +21. GvHD prophylaxis 
was performed from day +15 to day +100 only with cyclosporine (CSA).
Subsequently various complications as consequence of the immunodefi-
ciency were diagnosed (esophagitis caused by reactivated CMV infection,
ambilateral pneumonia with suspicion of aspergillosis, maxillary sinusi-
tis). 9 months after transplantation the patient developed a histologically
proven chronic GvHD of the skin and gastrointestinal tract (extensive
disease) that was successfully treated with prednisolone. Because of unac-
ceptable side effects (muscular atrophy, depression, insomnia) the appli-
cation of prednisolone had to be stopped and from day +210 the immuno-
suppression was continued with CSA. 4 months later (day +312) the pa-
tient had to be admitted to hospital with peripheral lymphomas, B symp-
toms (fever up to 40 °C, weight loss of 6 kg in 3 months) and physical
weakness. Neurological symptoms including tremor, hypersensitivity to
light and touch, imbalances and insecurity in walking were observed. An
ultrasound scan showed enlarged lymph nodes (cervical, axillary, in-
guinal) up to 2.4 cm in diameter. As signs of increased cell proliferation
lactate dehydrogenase (LDH) as well as thymidine kinase (TK) levels in
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Fig. 1. Cytological examination of cervical lymph node showed immunoblasts
with partial differentiation to plasma cells (100:1; Pappenheim’s stain).
Fig. 2. A. Histological examination revealed polymorphous B-cell proliferation
type of EBV-associated PTLD. The majority of tumor cells are large blasts with
prominent nucleoli and pale basophilic cytoplasm (200:1, Giemsa). B. The tumor
cells were positive for EBV-latent membrane protein-1 (200:1; ABC method).
the serum were significantly increased. In contrast, the CD4 count in the
peripheral blood (43 cells/mm3) and the CD4/CD8 ratio (0.17), respec-
tively, were considerably reduced. 
The biopsy and subsequent cytological examination of a cervical lymph
node first confirmed the suspicion of an aggressive non-Hodgkin’s lym-
phoma with detection of immunoblasts (fig. 1). Histologically a polymor-
phe EBV-PTLD was diagnosed (fig. 2A) with detection of CD20-, partial-
ly also CD30-positive blasts, expression of immunoglobulin kappa- and
lambda light chains as well as the EBV-antigen LMP-1 (latent membrane
protein) (fig. 2B). The clonality could be proven by detection of the re-
arrangement of the immunoglobulin heavy chain gene. In addition, the
examination of the cerebrospinal fluid (CSF) revealed a polymorphic
meningeosis lymphoblastica as cause of the neurological symptoms (fig.
3). A magnetic resonance tomography (MRT) scan of the skull showed
meningeal irritations in the area of the frontal brain. The polymerase
chain reaction (PCR) was positive for EBV-DNA in the peripheral blood
and in CSF. 
First, immunosupression with CSA was stopped on day +312. Because of
the preexisting chronic GvHD as well as the unsatisfactory results with
cytotoxic agents, we started a treatment with Rituximab (375 mg/m2 i.v.
on days +316, +323, +330, +337) [Europe: Mabthera®, Hoffmann-La
Roche, Grenzach-Wyhlen, Germany; USA: Rituxan®,  IDEC Pharma-
ceuticals, San Diego, CA; Genentech, San Francisco, CA] and Cidofovir
(5 mg/kg i.v. on days +317, +324, +331) [Vistide®, Pharmacia & Upjohn,
Erlangen, Germany]. Subsequently we observed a rapid improvement of
the general condition of the patient with complete regression of the pe-
ripheral lymphomas and disappearance of the neurological symptoms.
The patient was discharged from hospital on day +338. The PCR control
on EBV-DNA first became negative only in the plasma while it still re-
mained positive in CSF (day +337). Therefore, we continued outpatient
the application of Cidofovir on days +348 and +362. Subsequently, also in
CSF the PCR on EBV-DNA became negative (day +378). 
Until day +440 the patient remained well without any signs of a nodular
or CNS relapse of the EBV-lymphoma. However, an ambilateral pneu-
monia caused by Aspergillus fumigatus was diagnosed. After develop-
ment of an ARDS the patient died on day +458 as a consequence of a
multiorgan failure. 
Discussion
EBV-associated PTLD is a serious complication in patients
with allogeneic HSCT after myeloablative as well as after
dose-modified conditioning. Treatment of choice is im-
munotherapy with immediate withdrawal of immunosuppres-
sion on the one hand and infusion of unselected donor leuko-
cytes or EBV specific cytotoxic donor T cells on the other
hand [1, 3, 8]. However, the potential alloreactivity of unma-
nipulated donor cells as well as the problems of a immediate
availability of unrelated donors can limit this therapeutic
option [1, 7]. Beside cytotoxic agents and various antiviral
drugs [10–13], positive results of the use of the monoclonal
anti-CD20 antibody rituximab were repeatedly reported [4,
16, 17]. 
The situation of our patient with CNS involvement appeared
difficult for different reasons. First, beside the discontinuation
of the immunosuppression an intensive immunotherapy (in-
cluding DLI) was impossible (preexisting GvHD, unrelated
donor). Treatment with chemotherapeutic agents was not
likely to be successful, since the results in patients with PTLD
are frequently unsatisfactory [6, 18]. On the other hand a very
limited number of cytotoxic drugs are able to cross the blood-
brain barrier [19]. Although the ability to penetrate into the
CNS is unknown with Rituximab [19, 20], we decided to use
this antibody because of its repeatedly reported effectiveness
in EBV-associated PTLD [4, 16, 17]. In addition, in patients
with CNS involvement by B-cell lymphoma the systemic
and/or intraventricular application of Rituximab were de-
scribed occasionally [20–24]. We combined Rituximab with
Cidofovir, its antiviral efficiency against EBV having been al-
ready examined [25, 26]. The clinical course of our patient
could indicate that Rituximab is effective not only in cases
with nodular manifestation of EBV-LPD. We have seen that
this antibody is active also in CNS despite low concentrations
in the CSF in comparison to serum levels described by several
authors [20, 22, 24]. 
Conclusion
As seen in our patient with meningeosis lymphoblastica
caused by a malignant EBV-associated lymphoma, it is possi-
ble to achieve complete remission without any systemic or in-
trathecal cytotoxic chemotherapy. This shows that the distur-
bance of the blood-brain-barrier, frequently observed in pa-
tients with CNS involvement, seems to play an important role.
Therefore, the systemic use of Rituximab in conventional dos-
es appears to be an interesting alternative treatment in pa-
tients with EBV-associated PTLD and CNS involvement.
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Fig. 3. Cytological detection of polymorphic immunoblasts and plasmoblastic
cells in the cerebrospinal fluid (meningeosis lymphoblastica caused by EBV-
PTLD) (100:1; Pappenheim’s stain).
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